The effects of PPAR gamma agonist rosiglitazone on neointimal hyperplasia in rabbit carotid anastomosis model

Creative Commons License

Guzeloglu M., REEL B., Atmaca S., BAĞRIYANIK H. A., Hazan E.

JOURNAL OF CARDIOTHORACIC SURGERY, vol.7, 2012 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 7
  • Publication Date: 2012
  • Doi Number: 10.1186/1749-8090-7-57
  • Journal Name: JOURNAL OF CARDIOTHORACIC SURGERY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Keywords: Neointima, Rosiglitazone, Matrix metalloproteinases (MMPs), Rabbit, MUSCLE-CELL PROLIFERATION, CORONARY-ARTERY-DISEASE, TISSUE INHIBITOR, VASCULAR INJURY, SAPHENOUS-VEIN, IN-VIVO, PTFE GRAFTS, MIGRATION, MATRIX, EXPRESSION
  • Dokuz Eylül University Affiliated: Yes

Abstract

Background: Neointimal hyperplasia involving smooth muscle cell (SMC) proliferation, migration and extracellular matrix (ECM) degradation is an important component of atherosclerosis. It develops as a response to vascular injury after balloon angioplasty and vascular graft placement. Matrix metalloproteinases (MMPs) induce SMC proliferation, migration and contribute to intimal hyperplasia by degrading ECM. PPAR. agonists inhibit SMC proliferation, migration and lesion formation. In this study, we aimed to investigate the effects of PPAR. agonist rosiglitazone on neointimal hyperplasia and gelatinase (MMP-2 and MMP-9) expressions in rabbit carotid anastomosis model.